170 related articles for article (PubMed ID: 34387808)
1. IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer.
Hu Y; Liu D; Cui P; Zhang W; Chen H; Piao C; Lu Y; Liu X; Wang Y; Liu J; Lu X
Invest New Drugs; 2021 Dec; 39(6):1538-1548. PubMed ID: 34387808
[TBL] [Abstract][Full Text] [Related]
2. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
3. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
[TBL] [Abstract][Full Text] [Related]
4. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
5. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
6. Interleukin-15-transferred cytokine-induced killer cells elevated anti-tumor activity in a gastric tumor-bearing nude mice model.
Peng Z; Liang W; Li Z; Xu Y; Chen L
Cell Biol Int; 2016 Feb; 40(2):204-13. PubMed ID: 26503216
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K
Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678
[TBL] [Abstract][Full Text] [Related]
9. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.
Namikawa T; Maeda H; Kitagawa H; Oba K; Tsuji A; Yoshikawa T; Kobayashi M; Hanazaki K
BMC Cancer; 2018 Feb; 18(1):186. PubMed ID: 29439671
[TBL] [Abstract][Full Text] [Related]
10. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
[TBL] [Abstract][Full Text] [Related]
12. Clinical Study on the Medical Value of Combination Therapy Involving Adoptive Immunotherapy and Chemotherapy for Stage IV Colorectal Cancer (COMVI Study).
Yoshida Y; Naito M; Yamada T; Aisu N; Kojima D; Mera T; Tanaka T; Naito K; Yasumoto K; Kamigaki T; Gotoh S; Kodama S; Yamashita Y; Hasegawa S
Anticancer Res; 2017 Jul; 37(7):3941-3946. PubMed ID: 28668898
[TBL] [Abstract][Full Text] [Related]
13. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.
Kang YK; Chin K; Chung HC; Kadowaki S; Oh SC; Nakayama N; Lee KW; Hara H; Chung IJ; Tsuda M; Park SH; Hosaka H; Hironaka S; Miyata Y; Ryu MH; Baba H; Hyodo I; Bang YJ; Boku N
Lancet Oncol; 2020 Aug; 21(8):1045-1056. PubMed ID: 32682457
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
Park SH; Lim DH; Sohn TS; Lee J; Zang DY; Kim ST; Kang JH; Oh SY; Hwang IG; Ji JH; Shin DB; Yu JI; Kim KM; An JY; Choi MG; Lee JH; Kim S; Hong JY; Park JO; Park YS; Lim HY; Bae JM; Kang WK;
Ann Oncol; 2021 Mar; 32(3):368-374. PubMed ID: 33278599
[TBL] [Abstract][Full Text] [Related]
15. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial.
Kono K; Takahashi A; Ichihara F; Amemiya H; Iizuka H; Fujii H; Sekikawa T; Matsumoto Y
Clin Cancer Res; 2002 Jun; 8(6):1767-71. PubMed ID: 12060615
[TBL] [Abstract][Full Text] [Related]
17. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients.
Jiang JT; Shen YP; Wu CP; Zhu YB; Wei WX; Chen LJ; Zheng X; Sun J; Lu BF; Zhang XG
World J Gastroenterol; 2010 Dec; 16(48):6155-62. PubMed ID: 21182234
[TBL] [Abstract][Full Text] [Related]
18. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
Su Y; Lin L; Zhang J; Jiang Y; Pan C; Sun L; Duan J; Liao W
Mol Med Rep; 2015 Oct; 12(4):5771-9. PubMed ID: 26239822
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of adoptive cellular therapy in patients with gastric cancer: a meta-analysis.
Shen D; Liu ZH; Xu JN; Xu F; Lin QF; Lin F; Mao WD
Immunotherapy; 2016 Jul; 8(8):971-81. PubMed ID: 27381688
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro.
Zhao Q; Zhang H; Li Y; Liu J; Hu X; Fan L
J Exp Clin Cancer Res; 2010 Aug; 29(1):118. PubMed ID: 20799994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]